Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities Autozi Internet Technology (Nasdaq: AZI) received a Nasdaq notification dated March 25, 2026 that it is not in compliance with the minimum Market Value of Listed Securities (MVLS) $50,000,000 requirement.The company reported its MVLS failed to meet the $50 million threshold for the 30 consecutive business days from February 10, 2026 to March 24, 2026. Autozi has a 180-calendar-day compliance period, until September 21, 2026, to regain compliance by reaching MVLS of $50 million or more for ten consecutive business days; trading is not affected at this time.

#AZI Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities

www.stocktitan.net/news/AZI/autozi-internet...

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS Amgen (NASDAQ:AMGN) reported that Repatha (evolocumab) reduced first major adverse cardiovascular events by 31% in a high-risk primary prevention subgroup from VESALIUS-CV.The analysis (3,655 patients with diabetes, median 4.8 years) showed median LDL-C 44 mg/dL at 96 weeks versus 105 mg/dL for placebo; results were presented at ACC and published in JAMA.

#AMGN REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

www.stocktitan.net/news/AMGN/repatha-cuts-r...

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care Takeda (NYSE:TAK) reported Phase 3 results showing once-daily oral zasocitinib (TAK-279) produced rapid, durable skin clearance in moderate-to-severe plaque psoriasis. At week 16, sPGA 0/1 rates were 71.4% and 69.2% versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%).PASI90 rates reached 61.3% and 51.9% at week 16; PASI100 reached 33.4% and 25.2%. Responses increased through week 24, and >90% of responders at week 40 maintained response at week 60. Safety was consistent with Phase 2b; no new safety signals. Takeda plans NDA submissions beginning fiscal 2026.

#TAK Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

www.stocktitan.net/news/TAK/takeda-s-zasoci...

NEJM study: rare muscle-skin disease drug beat placebo in Phase 3 The 241-patient trial showed benefits by Week 4 through Week 52, while nearly twice as many patients cut steroids. FDA action is due in Q3 2026.

#ROIV #ROIVW New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

www.stocktitan.net/news/ROIV/new-england-jo...

Skin disease trial shows 62% response at 40 weeks, no new safety signals Up to 32% reached HiSCR100 and 25% achieved inflammatory remission in Phase 3 HS trials. MoonLake expects 52-week data in Q2 2026.

#MLTX MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

www.stocktitan.net/news/MLTX/moon-lake-anno...

After a year, Incyte’s oral HS drug showed durable gains in Phase 3 Up to 57% of patients hit HiSCR75 and 29% reached HiSCR100 at Week 54, with safety in line with prior data as U.S. and EU reviews continue.

#INCY Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

www.stocktitan.net/news/INCY/incyte-announc...

Over a quarter of resistant hypertension patients had hypercortisolism MOMENTUM screened 1,086 patients; prevalence rose to 32.6% in those with high HbA1c on 3+ blood pressure drugs, supporting screening.

#CORT Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

www.stocktitan.net/news/CORT/corcept-presen...

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Nektar Therapeutics (Nasdaq:NKTR) presented Phase 2b and Phase 2b/extension data for rezpegaldesleukin at AAD 2026 showing efficacy across moderate-to-severe atopic dermatitis and activity in alopecia areata.In REZOLVE-AD (393 patients) rezpegaldesleukin produced consistent mean EASI improvement and comparable EASI-75/90 responses across baseline vIGA-AD severity and regions. A Phase 3 ZENITH-AD program is planned to start in Q2 2026. In alopecia areata, high-dose rezpegaldesleukin showed greater SALT reduction versus placebo, with statistical significance achieved under specified exclusions; safety was consistent and well tolerated.

#NKTR Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

www.stocktitan.net/news/NKTR/data-from-phas...

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four

#ARQT Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

www.stocktitan.net/news/ARQT/arcutis-presen...

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting Kymera Therapeutics (NASDAQ: KYMR) reported positive Phase 1b BroADen results for oral STAT6 degrader KT-621, presented at AAD 2026. In 22 moderate-to-severe atopic dermatitis patients, 28-day dosing produced median STAT6 degradation up to 98% in blood and meaningful reductions in clinical and biomarker endpoints.Parallel Phase 2b trials in atopic dermatitis (BROADEN2) and asthma (BREADTH) are ongoing, with data expected by mid-2027 and late-2027, respectively.

#KYMR Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

www.stocktitan.net/news/KYMR/kymera-therape...

Gemini Space Station, Inc. Class Action Lawsuit: Investors Face May 18, 2026, Deadline {"summary":"","positive":[],"negative":[],"faq":[]}

#GEMI Gemini Space Station, Inc. Class Action Lawsuit: Investors Face May 18, 2026, Deadline

www.stocktitan.net/news/GEMI/gemini-space-s...

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism Boston Scientific (NYSE: BSX) reported that the randomized HI-PEITHO trial met its primary endpoint: EKOS plus anticoagulation was superior to anticoagulation alone for intermediate-risk pulmonary embolism (4.0% vs. 10.3%; P=0.005), a 61% relative reduction in events.Trial enrolled 544 patients across 59 U.S. and European sites; no intracranial bleeding through 30 days; patients will be followed to one year.

#BSX HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

www.stocktitan.net/news/BSX/hi-peitho-trial...

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis Johnson& Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies. Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD study. SPRING HOUSE, Pa., March 28, 2026/ PRNewswire/-- Johnson& Johnson today announced new long-term 52- week...

#JNJ ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

www.stocktitan.net/news/JNJ/icotydetm-icotr...

Patients stayed stable after switching to Bristol Myers' Cobenfy About 86% completed 8 weeks, and no patients stopped Cobenfy for lack of efficacy, giving clinicians data on faster and slower switch strategies.

#BMY Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

www.stocktitan.net/news/BMY/open-label-outp...

Visa, Street Soccer USA and Bank of America to Bring Visa Street Soccer Parks to Every FIFA World Cup 2026™ Host City in the U.S. Visa (NYSE:V), together with Street Soccer USA and Bank of America, announced expansion of Visa Street Soccer Parks to every FIFA World Cup 2026™ U.S. host city, adding parks in Boston, Dallas/Fort Worth, Houston, Los Angeles, Miami, Philadelphia and Seattle/Tacoma.Each park features two professional-grade Bank of America fields, lighting, learning centers and community programming; Visa will also launch Visa & Main to support local small businesses around the parks.

#V #BAC Visa, Street Soccer USA and Bank of America to Bring Visa Street Soccer Parks to Every FIFA World Cup 2026™ Host City in the U.S.

www.stocktitan.net/news/V/visa-street-socce...

Rocket Lab’s 85th launch puts Europe’s new navigation test in orbit Electron placed ESA’s first two Celeste spacecraft into 510 km orbit, testing navigation tech for autonomous vehicles, emergency services and networks.

#RKLB Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency

www.stocktitan.net/news/RKLB/rocket-lab-suc...

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon), a

#VVY Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

www.stocktitan.net/news/VVY/vivoryon-therap...

Kyndryl Holdings, Inc. Notice of April 13, 2026 Application Deadline for Class Action Lawsuits - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline NEW YORK and NEW ORLEANS, March 28, 2026

#KD Kyndryl Holdings, Inc. Notice of April 13, 2026 Application Deadline for Class Action Lawsuits - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

www.stocktitan.net/news/KD/kyndryl-holdings...

Navan, Inc. Notice of April 24, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline {"summary":"","positive":[],"negative":[],"faq":[]}

#NAVN Navan, Inc. Notice of April 24, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

www.stocktitan.net/news/NAVN/navan-inc-noti...

Osisko Development Reports Fourth Quarter and Year-End 2025 Results Osisko Development (NYSE: ODV) reported Q4 2025 and year-end results with $422.3M cash, Q4 revenue of $24.2M from 3,970 ounces sold, and $145.8M outstanding under the US$450M project loan.Key 2025 actions: private placement ~$82.5M, subsequent prospectus raise ~US$143.8M, warrants proceeds ~$24.9M, Cariboo drilling ~11,025m (~80% of program), and sale of San Antonio closed.

#ODV Osisko Development Reports Fourth Quarter and Year-End 2025 Results

www.stocktitan.net/news/ODV/osisko-developm...

BlackRock trims Caledonia holding, but still controls 6.56% BlackRock's total position fell to 6.56% from 6.57%, including 1,268,587 voting rights. The threshold filing reached Caledonia on March 26.

#CMCL Notification of Relevant Change to Significant Shareholder

www.stocktitan.net/news/CMCL/notification-o...

Fermi America™ Files Second Clean Air Permit Application with TCEQ for 5 GW of Additional Power for Its Project Matador Private Grid Fermi America (NASDAQ: FRMI) filed a 5 GW Clean Air Permit Application with the Texas Commission on Environmental Quality on March 27, 2026, following TCEQ’s approval of a first ~6 GW permit on February 25, 2025.The company targets ~17 GW total capacity composed of ~11 GW clean natural gas, plus nuclear, solar and battery power, and says ~2.5 GW of gas-fired combined-cycle generation is secured and equipment finance is committed.

#FRMI Fermi America™ Files Second Clean Air Permit Application with TCEQ for 5 GW of Additional Power for Its Project Matador Private Grid

www.stocktitan.net/news/FRMI/fermi-america-...

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report Lantern Pharma (NASDAQ: LTRN) confirmed that Panna Sharma remains President, CEO, and director after a false third‑party article claimed he stepped down. The board affirmed confidence, cited a recently cleared IND for STAR-001 pediatric CNS trial, and warned of potential market manipulation while investigating and considering legal and regulatory referrals.The company reiterated reliance on official SEC filings and its investor site and noted a webcast on March 30, 2026 at 4:30 p.m. ET to review FY2025 results.

#LTRN Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

www.stocktitan.net/news/LTRN/lantern-pharma...

Kolibri Global Energy Inc. Announces Director Nominees for Upcoming Shareholder Meeting Kolibri Global Energy (NASDAQ: KGEI, TSX: KEI) announced its board will nominate three new director candidates proposed by Tetragon Partners UK LLP for election at the annual meeting expected on May 4, 2026.Management nominees include existing directors David Neuhauser and CEO Wolf Regener plus new nominees Glen Brown, Lee Canaan and Murray Grigg. Chairman Evan Templeton, Douglas Urch and Leslie O’Connor will not stand for re-election; Mr. Templeton will assist with transition. Further nominee details will appear in the company’s management information circular to be mailed to shareholders and filed on SEDAR+.

#KGEI Kolibri Global Energy Inc. Announces Director Nominees for Upcoming Shareholder Meeting

www.stocktitan.net/news/KGEI/kolibri-global...

Antanas Guoga Announces Filing of Early Warning Report Related to Sol Strategies Inc. Antanas Guoga filed an early warning report dated March 27, 2026, disclosing a debt-settlement acquisition of 2,300,726 common shares of Sol Strategies (STKE) at a deemed issuance price of CAD$2.41 per share and subsequent market disposals.Prior to the debt settlement Mr. Guoga held 3,844,634 shares (≈11.89%). After the settlement he held 6,145,360 shares (≈18.85%), and following disposals of 725,581 shares between March 5–27, 2026 he now holds 5,419,778 shares (≈16.31%). Mr. Guoga said he will continue to review his investment and may increase, decrease or hedge his position.

#STKE Antanas Guoga Announces Filing of Early Warning Report Related to Sol Strategies Inc.

www.stocktitan.net/news/STKE/antanas-guoga-...

Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder Caledonia Mining (AIM:CMCL; NYSE AMERICAN:CMCL) received a TR-1 notification that BlackRock, Inc. crossed a relevant threshold on 26 March 2026. BlackRock's resulting position is 6.55% total voting rights (1,265,920 votes): 5.18% direct (1,001,011 shares) plus 1.37% via financial instruments (securities lending and CFDs).The issuer was notified on 27 March 2026; the prior reported total was 6.56%.

#CMCL Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder

www.stocktitan.net/news/CMCL/caledonia-mini...

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 Enveric Biosciences (NASDAQ: ENVB) reported fourth-quarter and year‑end 2025 results and operational updates on March 27, 2026. Key points: positive preclinical data for EB-003 in models of severe chronic depression and PTSD, FDA feedback allowing a streamlined IND plan, multiple patent issuances and a withdrawn PGR petition, manufacturing CMC milestones, a 1-for-12 reverse stock split, and $4.7M cash on hand at year‑end.The company raised $12.2M in fiscal 2025 (including $4.9M in Q4) and reported a Q4 net loss attributable to stockholders of $4.0M (loss per share $6.12).

#ENVB Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

www.stocktitan.net/news/ENVB/enveric-biosci...

Magna posts audited 2025 results ahead of May 4 virtual meeting The filing includes audited financial statements, MD&A, AIF and Form 40-F, giving shareholders key documents to review before Magna's May 4 meeting.

#MGA Magna Posts 2025 Annual Report

www.stocktitan.net/news/MGA/magna-posts-202...

Electra Restarts Construction and Reports 2025 Financial Results Electra (NASDAQ: ELBM) restarted full construction of its permitted cobalt sulfate refinery after a 2025 recapitalization. The Board approved a US$73 million construction budget; US$82 million of funding was arranged, including US$20 million from the U.S. Department of War and US$34 million equity.Early works completed; commissioning is expected Q4 2026, mechanical completion targeted Q2 2027, and commercial production anticipated Q4 2027. Cash was C$39 million at Dec 31, 2025 and about C$41 million currently.

#ELBM Electra Restarts Construction and Reports 2025 Financial Results

www.stocktitan.net/news/ELBM/electra-restar...

To keep Nasdaq listing, NextPlat combines every 10 shares into 1 Outstanding shares fall from 27.0M to about 2.7M as NextPlat seeks Nasdaq bid-price compliance. Split-adjusted trading begins April 7.

#NXPL #NXPLW NextPlat Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

www.stocktitan.net/news/NXPL/next-plat-anno...